Table 1.

Novel immunecheckpoint inhbitors.

Agent	Class	Phase	Trial ID	Status on ClinicalTrials.gov (Accessed on 10 October 2021)
relatlimab + nivolumab (RELATIVITY-047)	anti-LAG3 + anti-PD-1	II/III	NCT03470922	active, not recruiting
relatlimab + nivolumab	anti-LAG3 + anti-PD-1	II	NCT03743766	recruiting
vibostolimab + pembrolizumab	anti-TIGIT + anti-PD-1	I/II	NCT04305054	recruiting
vibostolimab + pembrolizumab + quavonlimab	anti-TIGIT + anti-PD-1 + anti-CTLA-4	I/II	NCT04305041	recruiting

LAG3: Lymphocyte Activating Gene 3; PD-1: Programmed Death 1; TIM-3: T-cell immunoglobulin and mucin domain 3, TIGIT: T cell immunoreceptor with Ig and ITIM domains, CTLA-4: Cytotoxic T-Lymphocyte Antigen 4.